Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Depressive symptoms and Depo-Provera

C Westhoff1, C Truman, D Kalmuss

  • 1College of Physicians and Surgeons, Columbia University, New York, New York, USA.

Contraception
|July 3, 1998
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Measurement of Time-Dependent CP Violation in the Flavor-Changing Neutral-Current Decay B^{0}→K_{S}^{0}μ^{+}μ^{-}.

Physical review letters·2026
Same author

Measurement of the Top-Quark Production Cross Section and Charge Asymmetry at LHCb.

Physical review letters·2026
Same author

Searches for B^{0}→K^{+}π^{-}τ^{+}τ^{-} and B_{s}^{0}→K^{+}K^{-}τ^{+}τ^{-} Decays.

Physical review letters·2026
Same author

First Evidence of the B_{s}^{0}→K^{-}π^{+}γ Decay.

Physical review letters·2026
Same author

Precision Measurement of CP Violation and Branching Fractions in B^{±}→K_{S}^{0}h^{±} (h=π, K) Decays and Search for the Rare Decay B_{c}^{±}→K_{S}^{0}K^{±}.

Physical review letters·2026
Same author

First Observation of the B[over ¯]_{s}^{0}→Λ_{c}^{+}Λ[over ¯]_{c}^{-} Decay and Evidence for the B[over ¯]^{0}→Λ_{c}^{+}Λ[over ¯]_{c}^{-} Decay.

Physical review letters·2026

Women using Depo-Provera (a contraceptive injection) showed fewer depressive symptoms at the start and experienced slight improvement after one year. Those with the most severe symptoms at enrollment saw the greatest improvement.

Area of Science:

  • Reproductive Health
  • Mental Health
  • Pharmacology

Background:

  • Contraceptive use is widespread among women of reproductive age.
  • Understanding the potential impact of hormonal contraceptives on mental health is crucial for patient counseling and care.
  • Depressive symptoms can affect women's quality of life and contraceptive adherence.

Purpose of the Study:

  • To investigate the relationship between depressive symptoms and the use of Depo-Provera (medroxyprogesterone acetate).
  • To assess changes in depressive symptom scores among women using Depo-Provera over a one-year period.

Main Methods:

  • A multicenter prospective study involving 495 women choosing Depo-Provera.
  • Baseline evaluation of depressive symptoms before initiating Depo-Provera.
Keywords:
AcceptorsAcceptors, New--womenAmericasCohort AnalysisContraceptionContraception TerminationContraceptive Agents, Female--side effectsContraceptive Agents, Progestin--side effectsContraceptive Agents--side effectsContraceptive Methods--side effectsDepo-provera--side effectsDepressionDeveloped CountriesDiseasesFamily PlanningFamily Planning ProgramsInjectables--side effectsMedroxyprogesterone Acetate--side effectsMental DisordersNorth AmericaNorthern AmericaProspective StudiesResearch MethodologyResearch ReportStudiesUnited States

Related Experiment Videos

  • Follow-up interviews at one year to reassess depressive symptom scores.

    • Main Results:

    • Women who continued using Depo-Provera had significantly lower baseline depressive symptom scores compared to those who discontinued or were lost to follow-up.
    • Among continuing users, depressive symptom scores showed a slight improvement from baseline to one year (7.4 vs. 6.7).
    • Women with the highest baseline depressive symptom scores experienced the most notable improvement at follow-up.

    Conclusions:

    • Depo-Provera use does not appear to be associated with an increase in depressive symptoms.
    • Women who continue Depo-Provera may experience a slight improvement in depressive symptoms over one year.
    • Depressive symptom severity at baseline may predict improvement during Depo-Provera use.